Advanced

Clinical significance of serum S100B levels in neurointensive care

Unden, Johan; Åstrand, Ramona LU ; Waterloo, Knut; Ingebrigtsen, Tor; Bellner, Johan LU ; Reinstrup, Peter LU ; Andsberg, Gunnar LU and Romner, Bertil LU (2007) In Neurocritical Care 6(2). p.94-99
Abstract
Objective S100B is viewed as the most promising biomarker for brain damage. It has been proposed that this marker is useful in a Neurointensive Care Unit (NICU) as a monitoring parameter. This study aims to examine the clinical usefulness of daily serum S100B measurements in this setting. Design Prospective consecutive inclusion of patients. Patients A total of 79 patients with confirmed or suspected head injury or cerebrovascular insults (CVIs) (based upon patient history, computed tomography (CT) and/or magnetic resonance imaging (MRI) and neurological examination including coma scoring) who required neurointensive care were included in the study. Interventions Sampling for S100B was performed at admission and daily until patients were... (More)
Objective S100B is viewed as the most promising biomarker for brain damage. It has been proposed that this marker is useful in a Neurointensive Care Unit (NICU) as a monitoring parameter. This study aims to examine the clinical usefulness of daily serum S100B measurements in this setting. Design Prospective consecutive inclusion of patients. Patients A total of 79 patients with confirmed or suspected head injury or cerebrovascular insults (CVIs) (based upon patient history, computed tomography (CT) and/or magnetic resonance imaging (MRI) and neurological examination including coma scoring) who required neurointensive care were included in the study. Interventions Sampling for S100B was performed at admission and daily until patients were discharged from the NICU. S100B measurements were statistically compared to occurrence of secondary complications and outcome according to Glasgow Outcome Scale (GOS), with focus on clinical prediction. Measurements and main results 17 of 79 patients (22%) had secondary neurological complications. Mean S100B levels were found to be an independent parameter associated with these complications (P = 0.03). Mean S100B levels were higher in patients with complications compared to those without on both the complication day (P = 0.033) and the day after (P = 0.015), but not the day prior to the complication (P = 0.62). S100B did not predict secondary neurological complication. Neither mean (P = 0.182) nor peak (P = 0.370) S100B levels were associated with or predicted outcome according to dichotornised GOS. Conclusion Daily S100B measurements are associated with secondary complications but not to outcome. However, daily S100B levels do not predict secondary complications, which limit the usefulness of this brain biomarker in this setting. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
secondary, monitoring, neurointensive, S100B/S-100/S100, neurocritical, complications, brain biomarker
in
Neurocritical Care
volume
6
issue
2
pages
94 - 99
publisher
Humana Press
external identifiers
  • wos:000247270700004
  • scopus:34250650088
ISSN
1541-6933
DOI
10.1007/s12028-007-0005-0
language
English
LU publication?
yes
id
953c3606-fd83-4296-87a5-e2424cabc1b3 (old id 648283)
date added to LUP
2007-12-19 11:07:27
date last changed
2017-09-24 03:34:10
@article{953c3606-fd83-4296-87a5-e2424cabc1b3,
  abstract     = {Objective S100B is viewed as the most promising biomarker for brain damage. It has been proposed that this marker is useful in a Neurointensive Care Unit (NICU) as a monitoring parameter. This study aims to examine the clinical usefulness of daily serum S100B measurements in this setting. Design Prospective consecutive inclusion of patients. Patients A total of 79 patients with confirmed or suspected head injury or cerebrovascular insults (CVIs) (based upon patient history, computed tomography (CT) and/or magnetic resonance imaging (MRI) and neurological examination including coma scoring) who required neurointensive care were included in the study. Interventions Sampling for S100B was performed at admission and daily until patients were discharged from the NICU. S100B measurements were statistically compared to occurrence of secondary complications and outcome according to Glasgow Outcome Scale (GOS), with focus on clinical prediction. Measurements and main results 17 of 79 patients (22%) had secondary neurological complications. Mean S100B levels were found to be an independent parameter associated with these complications (P = 0.03). Mean S100B levels were higher in patients with complications compared to those without on both the complication day (P = 0.033) and the day after (P = 0.015), but not the day prior to the complication (P = 0.62). S100B did not predict secondary neurological complication. Neither mean (P = 0.182) nor peak (P = 0.370) S100B levels were associated with or predicted outcome according to dichotornised GOS. Conclusion Daily S100B measurements are associated with secondary complications but not to outcome. However, daily S100B levels do not predict secondary complications, which limit the usefulness of this brain biomarker in this setting.},
  author       = {Unden, Johan and Åstrand, Ramona and Waterloo, Knut and Ingebrigtsen, Tor and Bellner, Johan and Reinstrup, Peter and Andsberg, Gunnar and Romner, Bertil},
  issn         = {1541-6933},
  keyword      = {secondary,monitoring,neurointensive,S100B/S-100/S100,neurocritical,complications,brain biomarker},
  language     = {eng},
  number       = {2},
  pages        = {94--99},
  publisher    = {Humana Press},
  series       = {Neurocritical Care},
  title        = {Clinical significance of serum S100B levels in neurointensive care},
  url          = {http://dx.doi.org/10.1007/s12028-007-0005-0},
  volume       = {6},
  year         = {2007},
}